Group 1 - The core issue involves a class action lawsuit filed against Biohaven Ltd. on behalf of investors who acquired its securities between March 24, 2023, and May 14, 2025 [1] - The lawsuit alleges that Biohaven misled investors regarding the regulatory prospects and efficacy of its drug candidates, specifically troriluzole for spinocerebellar ataxia and BHV-7000 for bipolar disorder [2] - The complaint claims that the overstated prospects of these drug candidates are likely to have a significant negative impact on Biohaven's business and financial condition once revealed [2] Group 2 - Shareholders interested in serving as lead plaintiffs must file their papers with the court by September 12, 2025, and participation in the case is not required to be eligible for recovery [3] - Robbins LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses [4] - The firm has been dedicated to helping shareholders recover losses and improve corporate governance since 2002 [4]